Maximising the use of pancreatic enzyme replacement therapy (PERT) among patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) and exocrine pancreatic insufficiency (EPI)

#4636

Introduction: Patients with GEPNENs frequently develop EPI due to surgical resection or use of somatostatin analogues (SSAs), however it is significantly underdiagnosed. Untreated EPI has significant impact on overall quality of life with patients with GEPNENs.

Aim(s): To investigate the rates of use of PERT among patients with GEPNENs and a formal diagnosis of EPI.

Materials and methods: We utilised the U.S. TriNetX Collaborative Network database to identify patients with GEPNENs and EPI (using ICD-10 codes). We then performed a comparative analysis between patients who were and were not prescribed PERT.

Conference:

Presenting Author:

Authors: Grewal U, Chandar A,

Keywords: Pancreatic insufficiency, Pancreatic enzyme replacement therapy, Gastroenteropancreatic neuroendocrine neoplasm,